Disease · MONDO_0006052

pulmonary tuberculosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pulmonary tuberculosis. Diseases, record MONDO_0006052. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006052

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pulmonary tuberculosis; Open Targets
Open Targets ID: MONDO_0006052; Open Targets
Other names: PTB, Tuberculosis, Pulmonary, lung TB, lung tuberculosis, pulmonary TB; Open Targets
Disease Ontology: DOID:2957; Disease Ontology
MeSH: D014397; MeSH
NCI Thesaurus: C26899; NCI Thesaurus
Highest stage of its drugs: Approval, for 15 of its 78 drugs, from DailyMed, FDA, PMDA and TTD; Open Targets

Drugs78

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PYRAZINAMIDE	CHEMBL614	Small molecule	Approval	DailyMed	42	41	40	Drugs and targets
RIFAMPIN	CHEMBL374478	Small molecule	Approval	DailyMed	37	34	32	Drugs and targets
ISONIAZID	CHEMBL64	Small molecule	Approval	DailyMed	36	33	32	Drugs and targets
ETHAMBUTOL	CHEMBL44884	Small molecule	Approval	TTD	24	23	23	Drugs and targets
PRETOMANID	CHEMBL227875	Small molecule	Approval	FDA	19	18	18	Drugs and targets
DELAMANID	CHEMBL218650	Small molecule	Approval	PMDA	17	16	16	Drugs and targets
ETHAMBUTOL HYDROCHLORIDE	CHEMBL3140361	Small molecule	Approval	DailyMed	15	1	1	Drugs and targets
CORTISONE ACETATE	CHEMBL1650	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets

1 to 10 of 78

See all 78 drugs

Targets69

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	6	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	2	HMG-CoA reductase inhibitor	Phase 2/3	https://conductscience.org/library/genes/3156	Drugs and targets
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Phase 3	https://conductscience.org/library/genes/7421	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/56901	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/2820	Drugs and targets
IFNGR1	Interferon gamma receptor	1	Interferon gamma receptor agonist	Phase 2	https://conductscience.org/library/genes/3459	Drugs and targets
IFNGR2	Interferon gamma receptor	1	Interferon gamma receptor agonist	Phase 2	https://conductscience.org/library/genes/3460	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Phase 3	https://conductscience.org/library/genes/4312	Drugs and targets

1 to 10 of 69

See all 69 targets

Trials113

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02410772	TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens	Phase 3	2,516	2021-09-28	Tuberculosis	MOXIFLOXACIN, RIFAPENTINE	Its record names the disease	ClinicalTrials.gov
NCT00864383	Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis	Phase 3	1,931	2015-05-25	Pulmonary Tuberculosis	ETHAMBUTOL, ISONIAZID, MOXIFLOXACIN, PYRAZINAMIDE, RIFAMPIN	Its record names the disease	ClinicalTrials.gov
NCT03338621	Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients	Phase 2/3	455	2023-11-08	Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR, Tuberculosis, Drug-Resistant Tuberculosis	BEDAQUILINE, MOXIFLOXACIN, PRETOMANID, PYRAZINAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00130247	Tuberculosis Treatment Shortening Trial	Phase 3	394	2010-01-27	Tuberculosis	ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN	Its record names the disease	ClinicalTrials.gov
NCT01785186	Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design	Phase 2	365	2017-09-20	Tuberculosis, Pulmonary	ISONIAZID, MOXIFLOXACIN, RIFAMPIN, SQ109	Its record names the disease	ClinicalTrials.gov
NCT02342886	Shortening Treatment by Advancing Novel Drugs	Phase 3	284	2019-03-26	Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant	MOXIFLOXACIN, PRETOMANID, PYRAZINAMIDE	Its record names the disease	ClinicalTrials.gov
NCT02193776	A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.	Phase 2	240	2019-07-26	Tuberculosis	BEDAQUILINE, MOXIFLOXACIN, PRETOMANID, PYRAZINAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01498419	Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)	Phase 2	207	2016-12-12	Pulmonary Tuberculosis	MOXIFLOXACIN, PRETOMANID, PYRAZINAMIDE	Its record names the disease	ClinicalTrials.gov
NCT02114684	Improving Retreatment Success (IMPRESS)	Phase 1/2	197	2019-08-05	Recurrent Tuberculosis	MOXIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT01408914	Trial of High-Dose Rifampin in Patients With TB	Phase 2	180	2017-07-13	Tuberculosis	ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 113

See all 113 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
4-Month Arm vs 6-Month Arm: Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat	13 of 196	3 of 198	394	NCT00130247	Trial comparisons
4-Month Arm vs 6-Month Arm: serious adverse events	19 of 196	22 of 198	394	NCT00130247	Trial comparisons
4-Month Arm vs 6-Month Arm: Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-TB Treatment - Per-protocol	13 of 185	3 of 185	370	NCT00130247	Trial comparisons
Drug Sensitive-TB 2HRZE/4HR vs Drug Sensitive-TB 4BPaMZ: Number of Participants With Culture Negative Status by 8 Weeks	70 of 148	122 of 145	293	NCT03338621	Trial comparisons
Moxifloxacin vs Control: Proportion of Patients With Any Grade 3 or 4 Adverse Reactions in the Two Study Arms	43 of 98	25 of 98	196	NCT02114684	Trial comparisons
Moxifloxacin vs Control: deaths from any cause	6 of 98	4 of 98	196	NCT02114684	Trial comparisons
Moxifloxacin vs Control: Proportion of Patients With Unfavourable Outcomes or Tuberculosis Recurrence in the Moxifloxacin and Control Arm.	13 of 98	6 of 98	196	NCT02114684	Trial comparisons
Moxifloxacin vs Control: serious adverse events	27 of 98	12 of 98	196	NCT02114684	Trial comparisons
Experimental Arm vs Control Arm: Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications	0 of 74	0 of 72	146	NCT00082173	Trial comparisons
Experimental Arm vs Control Arm: serious adverse events	6 of 74	6 of 72	146	NCT00082173	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials117

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40645198	RESULT	1	PubMed
38768617	RESULT	1	PubMed
36808186	RESULT	1	PubMed
30157391	RESULT	1	PubMed
28559269	RESULT	1	PubMed
25880846	RESULT	1	PubMed
25795076	RESULT	1	PubMed
25196020	RESULT	1	PubMed
23317958	RESULT	1	PubMed
22850121	RESULT	1	PubMed

1 to 10 of 117

See all 117 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006052

GET https://conductscience.org/api/diseases/v1/MONDO_0006052/drugs?page=2

API reference For AI assistants